Drug Shortage Report for INTEGRILIN
| Report ID | 149545 |
| Drug Identification Number | 02240352 |
| Brand name | INTEGRILIN |
| Common or Proper name | Eptifibatide Injection |
| Company Name | MERCK CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | EPTIFIBATIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1 |
| ATC code | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2021-11-26 |
| Actual start date | 2021-11-24 |
| Estimated end date | 2022-03-29 |
| Actual end date | 2022-03-22 |
| Shortage status | Resolved |
| Updated date | 2022-03-23 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
| Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v19 | 2022-03-23 | English | Compare |
| v18 | 2022-03-22 | French | Compare |
| v17 | 2022-03-22 | English | Compare |
| v16 | 2022-02-17 | French | Compare |
| v15 | 2022-02-17 | English | Compare |
| v14 | 2022-02-02 | French | Compare |
| v13 | 2022-02-02 | English | Compare |
| v12 | 2022-01-05 | French | Compare |
| v11 | 2022-01-05 | English | Compare |
| v10 | 2021-12-08 | French | Compare |
| v9 | 2021-12-08 | English | Compare |
| v8 | 2021-11-25 | English | Compare |
| v7 | 2021-11-24 | French | Compare |
| v6 | 2021-11-24 | English | Compare |
| v5 | 2021-11-22 | French | Compare |
| v4 | 2021-11-22 | English | Compare |
| v3 | 2021-11-18 | French | Compare |
| v2 | 2021-11-18 | English | Compare |
| v1 | 2021-11-18 | English | Compare |
Showing 1 to 19 of 19